Skip to main content

 Related scientific articles (all)

Harmonization of the evaluation of tumor infiltrating lymphocytes (TILs) in breast cancer: recommendations by an international TILs-working group 2014.

Authors : Salgado R, Denkert C, Demaria S, Sirtaine N, Klauschen F, Pruneri G, Wienert S, Van den Eynden G, Baehne FL, Penault-Llorca F, Perez EA, Thompson EA, Symmans WF, Richardson AL, Brock J, Criscitiello C, Bailey H, Ignatiadis M, Floris G, Sparano J, Kos Z, Nielsen T, Rimm DL, Allison KH, Reis-Filho JS, Loibl S, Sotiriou C, Viale G, Badve S, Adams S, Willard-Gallo K, Loi S
Year : 2015
Journal : Ann Oncol
Volume : 26(2)
Pages : 259-71

Exploring the safety of chemotherapy for treating breast cancer during pregnancy.

Authors : Lambertini M, Kamal NS, Peccatori FA, Del Mastro L, Azim HA
Year : 2015
Journal : Expert Opin Drug Saf
Volume : 14(9)
Pages : 1395-408

Predicting Anthracycline Benefit: TOP2A and CEP17-Not Only but Also.

Authors : Bartlett JM, McConkey CC, Munro AF, Desmedt C, Dunn JA, Larsimont D, O Malley FP, Cameron DA, Earl HM, Poole CJ, Shepherd LE, Cardoso F, Jensen MB, Caldas C, Twelves CJ, Rea DW, Ejlertsen B, Di Leo A, Pritchard KI
Year : 2015
Journal : J. Clin. Oncol.
Volume : 33(15)
Pages : 1680-7

Tumor-Infiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy With or Without Carboplatin in Human Epidermal Growth Factor Receptor 2-Positive and Triple-Negative Primary Breast Cancers.

Authors : Denkert C, Von Minckwitz G, Brase JC, Sinn BV, Gade S, Kronenwett R, Pfitzner BM, Salat C, Loi S, Schmitt WD, Schem C, Fisch K, Darb-Esfahani S, Mehta K, Sotiriou C, Wienert S, Klare P, André F, Klauschen F, Blohmer J, Krappmann K, Schmidt M, Tesch H, Kümmel S, Sinn P, Jackisch C, Dietel M, Reimer T, Untch M, Loibl S
Year : 2015
Journal : J. Clin. Oncol.
Volume : 33(9)
Pages : 983-91

Evolution In the therapeutic strategy of localized resectable pancreatic ductal adenocarcinoma.

Authors : Van Daele D, Puleo F, Dumont R, Polus M, Loly C, Martinive P, Meunier P, Collignon J, Hendlisz A, Maréchal R, Louis E, Van Laethem JL
Year : 2015
Journal : Rev Med Suisse
Volume : 11
Pages : 1543-8

Disappearance of Upper Urinary Tract Urothelial Carcinoma after Treatment of a Borderline Brenner Tumor: Case Report and Literature Review.

Authors : Aoun F, Kourie HR, Sirtaine N, Hawaux E
Year : 2015
Journal : Oncol Res Treat
Volume : 38(7-8)
Pages : 379-81

Duration of endocrine therapy and its impact on the results of adjuvant trials in premenopausal breast cancer patients.

Authors : Fouad TM, de Azambuja E, Azim HA
Year : 2015
Journal : Ann Oncol
Volume : 26(7)
Pages : 1511

Health-related quality of life in patients with locally advanced or metastatic breast cancer treated with eribulin mesylate or capecitabine in an open-label randomized phase 3 trial.

Authors : Cortes J, Hudgens S, Twelves C, Perez EA, Awada A, Yelle L, McCutcheon S, Kaufman PA, Forsythe A, Velikova G
Year : 2015
Journal : Breast Cancer Res Treat
Volume : 154
Pages : 509-20

St Gallen International Expert Consensus on the primary therapy of early breast cancer: an invaluable tool for physicians and scientists.

Authors : Ignatiadis M, Buyse M, Sotiriou C
Year : 2015
Journal : Ann Oncol
Volume : 26(8)
Pages : 1519-20

CCR 20th Anniversary Commentary: Gene-Expression Signature in Breast Cancer-Where Did It Start and Where Are We Now?

Authors : Gingras I, Desmedt C, Ignatiadis M, Sotiriou C
Year : 2015
Journal : Clin Cancer Res
Volume : 21
Pages : 4743-6

Iterative and prolonged remission in metastatic breast cancer using pegylated irinotecan: a case report.

Authors : Amzerin M, Mokrim M, Errihani H, Piccart-Gebhart M
Year : 2015
Journal : J Med Case Rep
Volume : 9
Pages : 5

Reactivation of multipotency by oncogenic PIK3CA induces breast tumour heterogeneity.

Authors : Van Keymeulen A, Lee MY, Ousset M, Brohée S, Rorive S, Giraddi RR, Wuidart A, Bouvencourt G, Dubois C, Salmon I, Sotiriou C, Phillips WA, Blanpain C
Year : 2015
Journal : Nature
Volume : 525(7567
Pages : 119-23

Etirinotecan pegol (NKTR-102) versus treatment of physician's choice in women with advanced breast cancer previously treated with an anthracycline, a taxane, and capecitabine (BEACON): a randomised, open-label, multicentre, phase 3 trial.

Authors : Perez EA, Awada A, OShaughnessy J, Rugo HS, Twelves C, Im SA, Gómez-Pardo P, Schwartzberg LS, Diéras V, Yardley DA, Potter DA, Mailliez A, Moreno-Aspitia A, Ahn JS, Zhao C, Hoch U, Tagliaferri M, Hannah AL, Cortes J
Year : 2015
Journal : Lancet Oncol
Volume : 16
Pages : 1556-68

A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS).

Authors : Cherny NI, Sullivan R, Dafni U, Kerst JM, Sobrero A, Zielinski C, de Vries EG, Piccart-Gebhart M
Year : 2015
Journal : Ann Oncol
Volume : 26
Pages : 1547-73

A prospective, observational grouped analysis to evaluate the effect of triptorelin on lower urinary tract symptoms in patients with advanced prostate cancer.

Authors : Gil T, Aoun F, Cabri P, Maisonobe P, Van Velthoven R
Year : 2015
Journal : Ther Adv Urol
Volume : 7(3)
Pages : 116-24

Discrepancies between ESMO and NCCN breast cancer guidelines: An appraisal.

Authors : Zagouri F, Liakou P, Bartsch R, Peccatori FA, Tsigginou A, Dimitrakakis C, Zografos GC, Dimopoulos MA, Azim HA
Year : 2015
Journal : Breast
Volume : 24(4)
Pages : 513-23

'New' metastases are associated with a poorer prognosis than growth of pre-existing metastases in patients with metastatic breast cancer treated with chemotherapy, Breast Cancer Research 2015, 17: 150

Authors : Twelves C, Cortes J, Kaufman PA, Yelle L, Awada A, Binder T, Olivo M, O Shaughnessy J, Jove M, Perez EA
Year : 2015
Journal : Breast Cancer Res
Volume : 17
Pages : 150

Constitutive phosphorylated STAT3-associated gene signature is predictive for trastuzumab resistance in primary HER2-positive breast cancer.

Authors : Sonnenblick A, Brohée S, Fumagalli D, Vincent D, Venet D, Ignatiadis M, Salgado R, Van den Eynden G, Rothé F, Desmedt C, Neven P, Loibl S, Denkert C, Joensuu H, Loi S, Sirtaine N, Kellokumpu-Lehtinen PL, Piccart-Gebhart M, Sotiriou C
Year : 2015
Journal : BMC Med
Volume : 13(1)
Pages : 177

Targeted agents for cancer treatment during pregnancy.

Authors : Lambertini M, Peccatori FA, Azim HA
Year : 2015
Journal : Cancer Treat Rev
Volume : 41(4)
Pages : 301-309

Checkpoint inhibitors in bladder and renal cancers: results and perspectives.

Authors : Aoun F, Kourie HR, Sideris S, Roumeguère T, Van Velthoven R, Gil T
Year : 2015
Journal : Immunotherapy
Volume : 7
Pages : 1259-71